COVID-19 era and GLP-1 RA era: Is it a renaissance when the dusk of global tragedy co-occurring with the dawn of magical remedy?

Abstract

The hypothesis is that the world should explore to either validate or refute whether glucagon-like peptide–1 receptor agonists (GLP-1 RAs) are drawing some if not all of their all-rounder multisystem capacities in general and their weight-reducing capabilities in particular as catalyzed by natural and/or vaccine-induced immunities against SARS-CoV-2 and their variants implicated as the causative agents for onset and evolution of COVID-19 pandemic globally. The simplest initial exploration could be healthcare systems running queries in their historical databases to assess whether patients who have been receiving GLP-1 RAs since before the pandemic are reporting significantly larger weight-loss since after the pandemic, and if it is so, then whether those significant results could be validated with laboratory and basic research to demonstrate antibodies against SARS-CoV-2 acting as catalysts for larger weight-loss with GLP-1 RAs.